These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 33988991)
21. Selectivity and activation of dopamine D3R from molecular dynamics. Feng Z; Hou T; Li Y J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545 [TBL] [Abstract][Full Text] [Related]
22. Lee JY; Kim HY; Martorano P; Riad A; Taylor M; Luedtke RR; Mach RH Front Neurosci; 2024; 18():1380009. PubMed ID: 38655111 [TBL] [Abstract][Full Text] [Related]
23. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor. Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D Cao Y; Sun N; Zhang J; Liu Z; Tang YZ; Wu Z; Kim KM; Cheon SH Medchemcomm; 2018 Sep; 9(9):1457-1465. PubMed ID: 30288220 [TBL] [Abstract][Full Text] [Related]
25. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Cosgrove KP; Veldhuizen MG; Sandiego CM; Morris ED; Small DM Synapse; 2015 Apr; 69(4):195-202. PubMed ID: 25664726 [TBL] [Abstract][Full Text] [Related]
26. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318 [TBL] [Abstract][Full Text] [Related]
27. Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors. Lee KH; Shi L J Chem Inf Model; 2024 Mar; 64(6):1778-1793. PubMed ID: 38454785 [TBL] [Abstract][Full Text] [Related]
28. Palmitoylation on the carboxyl terminus tail is required for the selective regulation of dopamine D2 versus D3 receptors. Zhang X; Le HT; Zhang X; Zheng M; Choi BG; Kim KM Biochim Biophys Acta; 2016 Sep; 1858(9):2152-2162. PubMed ID: 27349735 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
30. Advances and challenges in the search for D Moritz AE; Free RB; Sibley DR Cell Signal; 2018 Jan; 41():75-81. PubMed ID: 28716664 [TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol. Paul NM; Taylor M; Kumar R; Deschamps JR; Luedtke RR; Newman AH J Med Chem; 2008 Oct; 51(19):6095-109. PubMed ID: 18774793 [TBL] [Abstract][Full Text] [Related]
32. Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. Tan L; Zhou Q; Yan W; Sun J; Kozikowski AP; Zhao S; Huang XP; Cheng J J Med Chem; 2020 May; 63(9):4579-4602. PubMed ID: 32282200 [TBL] [Abstract][Full Text] [Related]
33. The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D Battiti FO; Cemaj SL; Guerrero AM; Shaik AB; Lam J; Rais R; Slusher BS; Deschamps JR; Imler GH; Newman AH; Bonifazi A J Med Chem; 2019 Jul; 62(13):6287-6314. PubMed ID: 31257877 [TBL] [Abstract][Full Text] [Related]
34. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464 [TBL] [Abstract][Full Text] [Related]
35. Dopamine D3 receptor modulates D2 receptor effects on cAMP and GABA release at striatopallidal terminals-Modulation by the Ca Villalobos-Escobedo FS; Jijón-Lorenzo R; Avalos-Fuentes JA; Paz-Bermúdez F; Recillas-Morales S; Rojas IC; Leyva-Gómez G; Cortés H; Florán B Eur J Neurosci; 2024 Apr; 59(7):1441-1459. PubMed ID: 38151481 [TBL] [Abstract][Full Text] [Related]
36. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933 [TBL] [Abstract][Full Text] [Related]
37. New tetrahydroisoquinoline-based D Cordone P; Namballa HK; Muniz B; Pal RK; Gallicchio E; Harding WW Bioorg Med Chem Lett; 2021 Jun; 42():128047. PubMed ID: 33882273 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882 [TBL] [Abstract][Full Text] [Related]
39. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363 [TBL] [Abstract][Full Text] [Related]
40. Dopamine D Gogarnoiu ES; Vogt CD; Sanchez J; Bonifazi A; Saab E; Shaik AB; Soler-Cedeño O; Bi GH; Klein B; Xi ZX; Lane JR; Newman AH J Med Chem; 2023 Feb; 66(3):1809-1834. PubMed ID: 36661568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]